Skip to main content

Plant-Derived and Endogenous Cannabinoids in Epilepsy

Clinical Drug Investigation volume 36, pages 331–340 (2016)Cite this article

Abstract

Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Ben Amar M, L´eonard L. Chapter 16: Cannabis. In: L´eonard L, Ben Amar M, editors. Les Psychotropes: Pharmacologie et Toxicomanie. Montreal: Les Presses de l’Universit´e de Montr´eal; 2002. p. 571–627.

  2. O’Shaugnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of Medical and Physical Society of Bengal, 1838–1840. p. 421–461.

  3. Robson P. Therapeutic aspects of cannabis and CBss. BrJ Psychiatry. 2001;178:107–15.

    CAS  Article  Google Scholar 

  4. Carter GT, Weijdt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. Drugs. 2004;75:464–70.

    Google Scholar 

  5. Fankhauser M. Chapter 4: history of cannabis in Western medicine. In: Grotenhermen F, Russo R, editors. Cannabis and CBss: pharmacology, toxicology and therapeutic potential. New York: The Haworth Integrative Healing Press; 2002. p. 37–51.

  6. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25.

  7. Mirken B. Marijuana on the state. Lancet. 2004;364:842.

    Article  PubMed  Google Scholar 

  8. Hoey J. Marijuana: federal smoke clears a little. CMAJ. 2001;164:1397.

    Google Scholar 

  9. Health Canada. Medical Use of Marihuana. Stakeholder Statistics. Ottawa: Office of Cannabis Medical Access, Health Canada; 2005. p. 2.

  10. Gorter RW, Butorac M, Pulido Cobian E, van der Sluis W. Medical use of cannabis in the Netherlands. Neurology. 2005;64:917–9.

    Article  PubMed  Google Scholar 

  11. Health Canada CIHR. Medical Marihuana Research Program. Ottawa: Health Canada and Canadian Institutes of Health Research; 1999. p. 7.

    Google Scholar 

  12. Health Canada [website]. Medical use of marijuana. Ottawa: Health Canada; 2015. Available from: http://www.hc-sc.gc.ca/dhp-mps/marihuana/index-eng.php. Accessed 10 July 2015.

  13. Collège des médecins du Québec. Guidelines concerning the prescription of dried cannabis for medical purposes. Montreal: Collège des médecins du Québec; 2014. Available from: http://www.cmq.org/en/MedecinsMembres/DossierMembreFormulaires/~/media/Files/Cannabis/Guidelinesprescription-cannabis.pdf?111402. Accessed 10 July 2015.

  14. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27.

    CAS  Article  PubMed  Google Scholar 

  15. McKim WA. Drugs and behavior. An introduction to behavioral pharmacology, 4th ed. Upper Saddle River: Prentice-Hall; 2000. p. 400.

  16. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62:588–631.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Fezza F, Bari M, Florio R, Talamonti E, Feole M, Maccarrone M. Endocannabinoids, related compounds and their metabolic routes. Molecules. 2014;19:17078–106.

    Article  PubMed  Google Scholar 

  18. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, Molinari M, Maccarrone M. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci. 2009;29:4564–70.

    CAS  Article  PubMed  Google Scholar 

  19. Ross RA. Allosterism and cannabinoid CB(1) receptors: the shape of things to come. Trends Pharmacol Sci. 2007;28:567–72.

    CAS  Article  PubMed  Google Scholar 

  20. Galve-Roperh I, Rueda D, Gómez del Pulgar T, Velasco G, Guzmán M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol. 2002;62:1385–92.

    CAS  Article  PubMed  Google Scholar 

  21. Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61:5784–89.

  22. Schmid HHO, Schmid PC, Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog Lipid Res. 1990;29:1–43.

    CAS  Article  PubMed  Google Scholar 

  23. Jin XH, Uyama T, Wang J, Okamoto Y, Tonai T, Ueda N. cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases. Biochim Biophys Acta. 2009;1791:32–8.

    CAS  Article  PubMed  Google Scholar 

  24. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279:5298–305.

    CAS  Article  PubMed  Google Scholar 

  25. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006;281:26465–72.

    CAS  Article  PubMed  Google Scholar 

  26. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G. A biosynthetic pathway for anandamide. Proc Natl Acad Sci. 2006;103:13345–50.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem. 2008;283:9341–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–7.

    CAS  Article  PubMed  Google Scholar 

  29. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569–78.

    CAS  Article  PubMed  Google Scholar 

  30. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem. 2005;280:11082–92.

    CAS  Article  PubMed  Google Scholar 

  31. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci. 2002;99:10819–24.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Navia-Paldanius D, Savinainen JR, Laitinen JT. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J Lipid Res. 2012;53:2413–24.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. Ueda N, Tsuboi K, Uyama T. Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J. 2013;280:1874–94.

    CAS  Article  PubMed  Google Scholar 

  35. Ueda N, Tsuboi K, Uyama T. N-Acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res. 2010;49:299–315.

    CAS  Article  PubMed  Google Scholar 

  36. Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011;111:5899–921.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010;51:768–72.

    CAS  Article  PubMed  Google Scholar 

  38. Soltesz I, Alger BE, Kano M, Lee SH, Lovinger DM, Ohno-Shosaku T, Watanabe M. Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat Rev Neurosci. 2015;16:264–77.

    CAS  Article  PubMed  Google Scholar 

  39. Wallace MJ, Blair RE, Falenski KW, Martin BR, De Lorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–37.

    CAS  Article  PubMed  Google Scholar 

  40. Fezza F, Marrone MC, Avvisati R, Di Tommaso M, Lanuti M, Rapino C, Mercuri NB, Maccarrone M, Marinelli S. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. Mol Cell Neurosci. 2014;62:1–9.

    CAS  Article  PubMed  Google Scholar 

  41. Citraro R, Russo E, Ngomba RT, Nicoletti F, Scicchitano F, Whalley BJ, Calignano A, De Sarro G. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res. 2013;106:74–82.

    CAS  Article  PubMed  Google Scholar 

  42. Rizzo V, Ferraro G, Carletti F, Lonobile G, Cannizzaro C, Sardo P. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci Lett. 2009;462:135–9.

    CAS  Article  PubMed  Google Scholar 

  43. Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci. 2003;23:3916–23.

    CAS  PubMed  Google Scholar 

  44. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol. 2007;558:52–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. Carletti F, Gambino G, Rizzo V, Ferraro G, Sardo P. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat. Neuroscience. 2015;303:149–59.

    CAS  Article  PubMed  Google Scholar 

  46. Shubina L, Aliev R, Kitchigina V. Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. Epilepsy Res. 2015;111:33–44.

    CAS  Article  PubMed  Google Scholar 

  47. Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059–66.

  48. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C. Lutz B CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–8.

    CAS  Article  PubMed  Google Scholar 

  49. Naidoo V, Karanian DA, Vadivel SK, Locklear JR, Wood JT, Nasr M, Quizon PM, Graves EE, Shukla V, Makriyannis A, Bahr BA. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase—dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics. 2012;9:801–13.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. Mechoulam R. Chapter 1: the pharmacohistory of Cannabis sativa. In: Mechoulan R, editor. CBss as therapeutic agents. Boca Raton: CRC Press; 1986. p. 1–19.

    Google Scholar 

  51. Consroe P, Wood JC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA. 1975;234:306–7.

    CAS  Article  PubMed  Google Scholar 

  52. Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry. 1990;51:439–40.

    CAS  PubMed  Google Scholar 

  53. Grinspoon L, Bakalar JB. Marihuana. The Forbidden Medicine. New Haven: Yale University Press; 1997. p. 296.

    Google Scholar 

  54. Gurley RJ, Aranow R, Katz M. Medicinal marijuana: a comprehensive review. J Psychoactive Drugs. 1998;30:137–47.

    CAS  Article  PubMed  Google Scholar 

  55. Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. 1975;12:1–15.

    CAS  PubMed  Google Scholar 

  56. Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.

    Google Scholar 

  57. Cortesi M, Fusar-Poli P. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med Hypotheses. 2007;68:920–1.

    CAS  Article  PubMed  Google Scholar 

  58. Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ. Arachidonyl- 2′-chloroethylamide, a highly selective CBs CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock- induced seizure model. Eur J Pharmacol. 2006;547:65–74.

    CAS  Article  PubMed  Google Scholar 

  59. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51:455–66.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266–72.

    CAS  Article  PubMed  Google Scholar 

  61. Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst. 1967;28:474–5.

    CAS  PubMed  Google Scholar 

  62. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers 2 and epileptic patients. Pharmacology. 1980;21:175–85.

    CAS  Article  PubMed  Google Scholar 

  63. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.

  64. Davis JP, Ramsey HH. Anti-epileptic action of marijuana active substances. Fed Proc. 1949;8:167.

    Google Scholar 

  65. Feeney DM. Marihuana use among epileptics. JAMA. 1976;235:1105.

    CAS  Article  PubMed  Google Scholar 

  66. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174–9.

    CAS  Article  PubMed  Google Scholar 

  67. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. In: Marijuana ’90 International Conference on Cannabis and Cannabinoids; 1990 July 8–11, section 2. Kolympari: International Association for CBs Medicines; 1990. p. 5.

  69. Dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015;40:135–43.

    Article  PubMed  Google Scholar 

  70. Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246–51.

    CAS  Article  PubMed  Google Scholar 

  71. Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88:730–6.

    CAS  Article  PubMed  Google Scholar 

  72. Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332–8.

    CAS  Article  PubMed  Google Scholar 

  73. Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363:1579–88.

    Article  PubMed  Google Scholar 

  74. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212–3.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574–7.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;10(373):1048–58.

    Google Scholar 

  77. Devinsky O, et al. Epidiolex (Cannabidiol) in treatment resistant epilepsy, American Epilepsy Society Annual Meeting, Poster, December 7, 2015.

  78. Lorentzos MS, Webster R. Cannabinoids for paediatric epilepsy: weeding out the issues. J Paediatr Child Health. 2015;51:476–7.

    Article  Google Scholar 

  79. Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav. 2014;41:277–82.

    Article  PubMed  Google Scholar 

  80. Ng SKC, Brust JCM, Hauser WA, Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol. 1990;132:47–57.

    CAS  PubMed  Google Scholar 

  81. Lorenz R. Experiences with THC-treatment in children and adolescents. In: IACM 2nd Conference on CBss in Medicine. Koeln: International Association for Cannabis as Medicine; 2003. p. 6.

  82. Gross DW, Hamm J, Ashowrth NL, Quigley D. Marijuana use and epilepsy. Neurology. 2004;62:2095–7.

    CAS  Article  PubMed  Google Scholar 

  83. Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis. 2007;4:103–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of L’Aquila, Ospedale “San Salvatore”, 67100, L’Aquila, Italy

    Alberto Verrotti

  2. Department of Pediatrics, University of Perugia, Ospedale “Santa Maria della Misericordia”, Sant’Andrea Delle Fratte, 06123, Perugia, Italy

    Miriam Castagnino

  3. Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128, Rome, Italy

    Mauro Maccarrone

  4. European Center for Brain Research/IRCCS Santa Lucia Foundation, Via del Fosso del Fiorano, 65, 00143, Rome, Italy

    Mauro Maccarrone & Filomena Fezza

  5. Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Via Montpellier 1, 00130, Rome, Italy

    Filomena Fezza

Authors
  1. Alberto Verrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miriam Castagnino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mauro Maccarrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filomena Fezza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Alberto Verrotti or Filomena Fezza.

Ethics declarations

Financial disclosure

The authors have no financial relationships to disclose with regard to this article.

Conflict of interest

AV, MC, MM and FF have no conflicts of interest.

Additional information

A. Verrotti, M. Maccarrone and F. Fezza are equally senior authors.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Verrotti, A., Castagnino, M., Maccarrone, M. et al. Plant-Derived and Endogenous Cannabinoids in Epilepsy. Clin Drug Investig 36, 331–340 (2016). https://doi.org/10.1007/s40261-016-0379-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-016-0379-x

Keywords

  • Fatty Acid Amide Hydrolase
  • Anticonvulsant Property
  • Medical Marijuana
  • Dravet Syndrome
  • Expanded Access Program